Synthesis Capital

Synthesis Capital targets investments in technologies and ventures that can change the face of global healthcare. Based in Australia and with a powerful pipeline across the Asia-Pacific region, Synthesis Capital invests in early-stage, deep technology medical, health and wellbeing-related ventures, from pre-seed to series A+. Structured as an Australian Early Stage Venture Capital Limited Partnership (ESVCLP) with a stapled managed investment trust, Synthesis Capital Fund I is built to optimise tax benefits for limited partners while maintaining investment flexibility. Synthesis Capital combines early-stage capital with market-leading venture development services – scaling its investment as risk is actively managed and addressed. Through powerful partnership with the MedTech Actuator – one of the Asia-Pacific’s leading medtech, healthtech and biotech venture development organisations – and its linkages across Singapore, India, South Korea and Japan, Synthesis Capital has direct access to a pipeline of investment-ready, high growth-potential enterprises, as well as the means to catalyse their development.